In vitro activity and fecal concentration of rifaximin after oral administration
about
Use of rifaximin in gastrointestinal and liver diseasesMechanism-Oriented Therapy of Irritable Bowel SyndromePart 2: Treatments for Chronic Gastrointestinal Disease and Gut DysbiosisAntimicrobial Resistance and Reduced Susceptibility in Clostridium difficile: Potential Consequences for Induction, Treatment, and Recurrence of C. difficile InfectionHigh frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital.In vitro antimicrobial susceptibility testing of bacterial enteropathogens causing traveler's diarrhea in four geographic regionsEfficacy of rifaximin compared with ciprofloxacin for the treatment of acute infectious diarrhea: a randomized controlled multicenter study.Travelers' diarrhea: antimicrobial therapy and chemoprevention.Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: a randomized, double-blind clinical trial.Effects of rifaximin administration on the intestinal microbiota in patients with ulcerative colitis.In vitro antimicrobial susceptibility of bacterial enteropathogens isolated from international travelers to Mexico, Guatemala, and India from 2006 to 2008Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential.In vitro activity and single-step mutational analysis of rifamycin SV tested against enteropathogens associated with traveler's diarrhea and Clostridium difficileSystemic absorption of rifamycin SV MMX administered as modified-release tablets in healthy volunteers.Expert review of the evidence base for self-therapy of travelers' diarrhea.Rifaximin for the treatment of acute infectious diarrheaImpact of rifaximin on the frequency and characteristics of spontaneous bacterial peritonitis in patients with liver cirrhosis and ascitesFuture novel therapeutic agents for Clostridium difficile infection.Rifaximin disc diffusion test for in vitro susceptibility testing of Clostridium difficile.Intestinal decolonization of Enterobacteriaceae producing extended-spectrum β-lactamases (ESBL): a retrospective observational study in patients at risk for infection and a brief review of the literature.Clostridium difficile drug pipeline: challenges in discovery and development of new agentsReview article: the antimicrobial effects of rifaximin on the gut microbiota.Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea.Rifaximin: a new treatment for travelers' diarrhea.Rifaximin for the treatment of irritable bowel syndrome - a drug safety evaluation.Small intestinal bacterial overgrowth is associated with irritable bowel syndrome and is independent of proton pump inhibitor usage.Rifaximin in the treatment of infectious diarrhea.Antibiotic-associated diarrhea and pseudomembranous colitis: are they less common with poorly absorbed antimicrobials?Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections.Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic.Prevention and treatment of traveler's diarrhea. Focus on antimicrobial agents.Systemic pharmacokinetics of rifaximin in volunteers with shigellosis.Current and future developments in travelers' diarrhea therapy.Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseasesRifamycin antibiotics for treatment of Clostridium difficile-associated diarrhea.The role of rifaximin in the treatment and chemoprophylaxis of travelers' diarrhea.Utility of the Nonabsorbed (<0.4%) Antibiotic Rifaximin in Gastroenterology and Hepatology.Rifaximin: a nonsystemic rifamycin antibiotic for gastrointestinal infections.Biologic properties and clinical uses of rifaximin.Rifaximin for the treatment of irritable bowel syndrome.
P2860
Q26740201-B4A6EFA8-0C7B-4574-9957-97FCDDBD30ABQ26747875-69C228D6-6CE9-480F-AA8C-077D2A39C134Q26771942-2615C2F0-94B4-4512-A5DD-045AC2C9E973Q28084026-EC93E4D9-AD50-47F7-AED1-AA2AAC1BD12FQ33641352-61B5EFD7-7408-4F00-AE19-137FC4CEFF50Q33981185-80254F50-1F8A-4A87-8DCA-5113EB2A8644Q34206683-1DA2ED38-7B78-4CEB-ABEB-2127BAAADA53Q34464671-1C6CAF92-848A-4F9E-AE3B-B3D69CA89CD9Q34519193-E53E0CFE-79A6-40E4-A53E-168CF88FBF4EQ34525343-E7EA2C65-5FEB-4468-84A3-312747E06D96Q34529094-04C8EB10-1968-4FFD-96F9-2D928A750565Q34557101-2F3CF498-246A-4C4B-9497-25D1250BFD71Q34737357-DFD81404-0592-49DC-AB52-E2CDA8B99348Q34932539-0EA741E2-89BB-443F-AAA3-4FD36C06B29BQ34987675-CC8265D2-091F-43F9-A1FA-1658815B7CE7Q35090413-12F72EE6-C0E0-4A8C-9E7F-A4EB9BB231CFQ35143004-035E7F88-81AF-400B-BCB1-5D2911FD48ECQ35175136-D6E6EC43-73B9-44A9-ABD4-7BC198BA4457Q35199060-E33209E3-479E-4E02-8CD6-2FAFC1137623Q35825390-87AA42DA-E2C8-438B-A8D0-4C2FD79EE065Q35846436-B2A03C52-9383-4A4E-808F-DEF38B0B27E6Q35855732-31E2C20F-A042-4C47-9747-616DFC627927Q35855740-741C7FBD-682E-4FB2-8CBE-039024E31288Q35983943-EF3E2938-E046-4308-9099-D03B800BD306Q36009729-78F082E5-6065-477C-9E7C-6A942B36C3F5Q36073385-7D09DD69-0171-4A32-8F8A-04BA6844344AQ36108487-B352D49D-DBF2-430E-97E1-A687D9C1B9DDQ36108490-D5640870-844A-4079-A9AB-BE312200C158Q36140657-E3F0C4C8-0F91-4019-9731-4AF9D80A6394Q36404922-D49FAC0D-D20C-47B0-9372-ED655C4A84B9Q36404962-4B9C3612-AC3F-45E4-AD62-88CB5E673E23Q36482910-08031D2D-AB3D-4918-9BCC-E6AF31AC7F09Q36505498-908CE960-3A6A-47DF-9A5C-B6B1ECBB4C8AQ36533648-C6CDFBAA-7B00-4CBC-8E8A-F4ADC3F610E1Q37145568-FD0C71A5-8A95-4678-92A8-E9040A98203FQ37412963-B07840D8-CE66-4CA6-8CDE-475A2E790AD3Q37678916-DA0D0A97-22F6-438F-BF61-1BDA53B1D67AQ37768415-D119A297-E580-4194-B39F-1AD27BA68942Q37827877-FE41C72B-5F0A-4D40-9537-14887EAB916FQ37976477-E4B97D27-E699-4129-8991-D4C3F80AF062
P2860
In vitro activity and fecal concentration of rifaximin after oral administration
description
2000 nî lūn-bûn
@nan
2000 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
In vitro activity and fecal concentration of rifaximin after oral administration
@ast
In vitro activity and fecal concentration of rifaximin after oral administration
@en
type
label
In vitro activity and fecal concentration of rifaximin after oral administration
@ast
In vitro activity and fecal concentration of rifaximin after oral administration
@en
prefLabel
In vitro activity and fecal concentration of rifaximin after oral administration
@ast
In vitro activity and fecal concentration of rifaximin after oral administration
@en
P2093
P2860
P1476
In vitro activity and fecal concentration of rifaximin after oral administration
@en
P2093
P2860
P304
P356
10.1128/AAC.44.8.2205-2206.2000
P407
P577
2000-08-01T00:00:00Z